The results indicated that pre‐treatment with PLCβ, PKCα and c‐Src inhibitors (U73122, GF109203X and PP2) reversed CXCL13‐promoted cell migration and VCAM‐1 in lung cancer cells (Figure 5A,B). Here, VCAM1 is linked to lung carcinoma.